With a little over 2 million shares in the float and a chart that looks like it's bouncing and building some serious steam....
It's No WONDER We have our eyes set on the one and only (NASDAQ:GTBP)
GT Biopharma (NASDAQ: GTBP): The Tiny NASDAQ Biotech with A Proprietary Cancer-Killing Platform, A $11 Price Target, And Multiple Bullish Catalysts!
Greetings All,
GTBP is standing out in the high-stakes battlefield in oncology….
The oncology sector is one of the most dynamic and lucrative areas in healthcare. Cancer remains a top global killer, and the demand for breakthrough therapies has never been greater. The companies that succeed in this fight not only transform patient outcomes but also deliver massive shareholder value.
Biotech innovators are often the first movers in immuno-oncology, gene therapy, and novel immune-modulating platforms — and GT Biopharma (NASDAQ: GTBP) is aggressively carving out its place in this revolution.
The next revolution in cancer immunotherapy is here.
GTBP isn't just another small-cap biotech. It's a clinical-stage disruptor armed with its proprietary TriKE® NK cell engager platform — a technology that unleashes the body's natural killer (NK) cells to hunt down and destroy cancer.
While other companies struggle with complex and costly CAR-T therapies, GTBP is delivering an off-the-shelf, highly scalable approach that could be faster, safer, and more versatile.
Its exclusive worldwide license from the University of Minnesota provides a powerful competitive moat that Big Pharma can't easily replicate!
Tapping into a multi-billion-dollar market
The global immuno-oncology market is expected to surge into the tens of billions over the next decade.
GTBP's TriKE® therapies stand at the center of this opportunity. Unlike CAR-T, which comes with severe side effects, limited solid tumor success, and expensive patient-by-patient engineering, TriKEs are modular, potent, and scalable. They bind NK cells directly to tumor cells, supercharge them with an IL-15 linker, and create a durable immune response that could overcome the weaknesses of first-generation therapies.
This is the kind of technology that attracts licensing deals, pharma partnerships, and — ultimately — buyout interest.
Gtb-3650 is advancing and momentum is building.
GTBP is already showing proof-of-concept.
Its second-generation candidate, GTB-3650, is moving through Phase 1 clinical trials for relapsed/refractory hematologic malignancies. After clearing the first two safety cohorts with no tolerability issues, the company has advanced to Cohort 3, signaling progress and confidence in the therapy's safety profile.
Early results have demonstrated clear NK cell activation and expansion — the kind of biomarker-driven validation investors want to see. Initial Phase 1 data is expected later in 2025, creating a major potential catalyst.
The pipeline: multiple shots on goal.
Beyond GTB-3650, the pipeline is stacked:
GTB-5550: Targeting solid tumors, where CAR-T therapies have largely failed.
GTB-7550: Targeting autoimmune diseases, expanding GTBP's platform beyond cancer into another multi-billion-dollar market.
With a well-capitalized balance sheet ($5.3M cash through Q1 2026) and an experienced leadership team, GTBP is positioned to execute on multiple fronts simultaneously.
An under-the-radar biotech gem.
GT Biopharma has the technology, catalysts, and exclusivity to ignite serious investor interest.
Roth MKM has already slapped an $11 price target on the stock — representing massive upside potential from current levels.
With trial momentum accelerating, IND submissions on deck, and platform expansion into solid tumors and autoimmune diseases, the company checks every box for a high-risk, high-reward biotech breakout.
This is a classic under-the-radar setup: tiny NASDAQ biotech, world-class proprietary platform, early clinical validation, and upcoming data releases.
Now is the time to watch GTBP!
GT Biopharma is an overlooked clinical-stage biotech on the cusp of making serious noise in immuno-oncology.
Its TriKE® platform could prove to be safer, more scalable, and more effective than CAR-T therapies — with far broader potential applications.
Multiple upcoming catalysts, strong insider leadership, and solid financing through 2026 make GTBP one of the most compelling speculative biotech plays in the market today.
Learn how GT Biopharma (NASDAQ: GTBP) is building the next wave of cancer immunotherapy — and how shareholders could benefit from this hidden biotech gem before Wall Street fully wakes up.
Disclaimer:
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Trading Wire nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Trading Wire. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Trading Wire makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
Some of the content on this website contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results.
Generally, the information regarding a company profiled or discussed on this website is provided from public sources tradingwire.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Trading Wire has no obligation to update any of the information provided. Trading Wire, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Trading Wire encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Trading Wire, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Trading Wire control, endorse, or guarantee any content found in such sites. Trading Wire does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Trading Wire, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Trading Wire, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Trading Wire uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your
future results or success, and are not responsible for your actions.
Trading Wire has been retained by Creative Direct Marketing to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from Creative Direct Marketing . Questions regarding this website may be sent to editor@tradingwire.com
Trading Wire has received a payment of $150,000.00 from Creative Direct Marketing for the marketing of Gt Bio Pharma (NASDAQ:GTBP) . which services include the issuance of this release and other opinions that we release concerning of Gt Bio Pharma (NASDAQ:GTBP) Trading Wire has not investigated the background of Creative Direct Marketing . Anyone viewing this newsletter should assume Creative Direct Marketing or affiliates of Creative Direct Marketing own shares of the Gt Bio Pharma (NASDAQ:GTBP) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Trading Wire has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Gt Bio Pharma (NASDAQ:GTBP)
